This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Comparison of Two Different Dosages of Low-molecular Weight Heparin in Cancer Patients

This study has been completed.
Information provided by:
Medical University of Vienna Identifier:
First received: September 11, 2006
Last updated: September 17, 2009
Last verified: September 2009
In a prospective, randomized, double-blind trial, the effects of two different dosages of LMWH (5000 anti-Xa U od sc and 10 000 anti-Xa U od sc daily) on markers of hemostatic system and thrombin generation will be investigated in non-surgical cancer patients will be investigated.

Condition Intervention Phase
Cancer Drug: enoxaparin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Official Title: Prevention of Venous Thrombosis in Cancer Patients: A Prospective, Randomized, Double-blind Study Comparing Two Different Dosages of Low-molecular Weight Heparin

Resource links provided by NLM:

Further study details as provided by Medical University of Vienna:

Study Start Date: June 2006
Study Completion Date: May 2008

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients (> 18 years) with active cancer and at least one of the following indications for thromboprophylaxis with LMWH:

  • Immobilization
  • History of VTE
  • Acute inflammation
  • Heart failure (NYHA class III or IV)
  • Respiratory failure

Exclusion Criteria:

  • Indication for LMWH or UFH at therapeutic dosages
  • Treatment with antithrombotics (vitamin K antagonists, acetylsalicylic acid, clopidogrel) for reasons other than prevention of VTE (e.g. atrial fibrillation, myocardial infarction)
  • Contraindication for the treatment with LMWH
  • Major surgery within the last 4 weeks; minor surgery within the last week
  • Thrombocytopenia (< 100.000/μl)
  • Prolonged prothrombin time
  • Prolonged activated partial thromboplastin time (aPTT)
  • History of heparin-induced thrombocytopenia
  • Bodyweight < 50 kg or > 100 kg
  • Renal insufficiency (creatinine > 2 mg/dl)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00375076

Medical University of Vienna
Vienna, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
Principal Investigator: Sabine Eichinger, MD Medical University of Vienna
  More Information

Responsible Party: Sabine Eichinger, Medical University of Vienna Identifier: NCT00375076     History of Changes
Other Study ID Numbers: ODEXA1
Study First Received: September 11, 2006
Last Updated: September 17, 2009

Additional relevant MeSH terms:
Heparin, Low-Molecular-Weight
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017